Home » Stocks » IMV

IMV Inc. (IMV)

Stock Price: $2.66 USD 0.05 (1.92%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $2.61 -0.05 (-1.88%) May 7, 7:49 PM
Market Cap 181.01M
Revenue (ttm) 236,078
Net Income (ttm) -27.34M
Shares Out 67.71M
EPS (ttm) -0.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $2.66
Previous Close $2.61
Change ($) 0.05
Change (%) 1.92%
Day's Open 2.61
Day's Range 2.55 - 2.68
Day's Volume 143,228
52-Week Range 2.18 - 6.82

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV to announce First Quarter 2021 Results and host conference call and Webcast on May 12, 2021

1 week ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference

3 weeks ago - Business Wire

Investors need to pay close attention to IMV stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Following feedback from the FDA, IMV Inc (NASDAQ: IMV) has inked an agreement with Merck & Co (NYSE: MRK) to initiate a Phase 2B trial evaluating IMV's lead compound, maveropepimut-S (DPX-Survivac), in ...

Other stocks mentioned: MRK
1 month ago - Benzinga

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)-- #DLBCL--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies...

1 month ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)---- $IMV--IMV Inc. (the "Company" or "IMV") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today...

1 month ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)---- $IMV--IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today...

1 month ago - Business Wire

IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV to Announce Fourth Quarter and Fiscal 2020 Financial and Operational Results

2 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV to Participate at the upcoming H.C. Wainwright Global Life Sciences Conference

2 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines agai...

4 months ago - Business Wire

Vancouver, British Columbia--(Newsfile Corp. - December 10, 2020) - On national TV Sat. Dec 12 & Sun. Dec 13, 2020 - BTV-Business Television spotlights the newest mining, cannabis, tech and pharmaceutic...

4 months ago - Newsfile Corp

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq:IMV; TSX:IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccin...

5 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against inf...

5 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...

5 months ago - Business Wire

IMV Inc. (IMV) CEO Frederic Ors on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Announces Third Quarter 2020 Financial Results and Provides Clinical Update

5 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...

5 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that the Company's T ce...

6 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...

6 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers

6 months ago - Business Wire

HALIFAX, Nova Scotia--(BUSINESS WIRE)---- $IMV #AntibioticDeveloper--Appili Announces Additional $6.3MM US Funding for its ATI-1701 Biodefense Program, working with Ology Bio on a vaccine candidate agai...

6 months ago - Business Wire

HALIFAX, Nova Scotia--(BUSINESS WIRE)---- $IMV #AntibioticDeveloper--Investigators enrolled and dosed the first cluster of participants in Appili's Phase 2 CONTROL clinical trial evaluating favipiravir ...

6 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Re-establishes At-the-Market Facility

6 months ago - Business Wire

IMV has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

6 months ago - Zacks Investment Research

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...

6 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...

7 months ago - Business Wire

Canada's IMV is a small but high-profile biotechnology company engaged in the development of a COVID-19 vaccine.

7 months ago - Seeking Alpha

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccine against infectious di...

7 months ago - Business Wire

IMV Inc. (IMV) CEO Frederic Ors on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

IMV INC (IMV) delivered earnings and revenue surprises of 25.00% and -42.86%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Announces Second Quarter 2020 Financial Results

8 months ago - Business Wire

IMV is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

8 months ago - Zacks Investment Research

IMV INC (IMV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

IMV (NASDAQ: IMV) shares are trading higher on Wednesday after the company announced it has received CA$4.75 million ($3.59 million) in funding from the Canadian government agencies for a COVID-19 vacci...

9 months ago - Benzinga

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...

9 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to Announce Second Quarter 2020 Results and Host a Conference Call and Webcast on August 12, 2020

9 months ago - Business Wire

As of late, it has definitely been a great time to be an investor in IMV Inc. (IMV).

9 months ago - Zacks Investment Research

IMV saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

Good news for Moderna was bad news for several of its rivals.

Other stocks mentioned: ALT, BNTX, INO, SRNE
9 months ago - The Motley Fool

IMV Inc. (NASDAQ: IMV) shares surged on Tuesday after the company provided an update on its vaccine candidate for COVID-19.

9 months ago - 24/7 Wall Street

Imv Inc (NASDAQ: IMV) share are ripping higher on above-average volume following an update by the company on its coronavirus vaccine program.

9 months ago - Benzinga

IMV Inc. (IMV) CEO Frederic Ors on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

IMV INC (IMV) delivered earnings and revenue surprises of -27.27% and 27.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

IMV, Inc. (IMV) CEO Frederic Ors on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Two coronavirus vaccine candidates are in the clinics and 42 more are in preclinical studies, according to updated data provided by the World Health Organization on March 20.

Other stocks mentioned: ALT, JNJ
1 year ago - Benzinga

IMV plans to develop a vaccine candidate using its lipid-based delivery platform, DPX technology, for the treatment of coronavirus disease. Stock rises.

1 year ago - Zacks Investment Research

Micro-cap Canadian biopharma Imv Inc (NASDAQ: IMV) said Wednesday that it is advancing the clinical development of a DPX-based vaccine candidate for the coronavirus, joining a number of biotechs working...

1 year ago - Benzinga

IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

About IMV

IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a ... [Read more...]

Industry
Biotechnology
Founded
2000
Stock Exchange
NASDAQ
Ticker Symbol
IMV
Full Company Profile

Financial Performance

In 2020, IMV Inc.'s revenue was 301,000, a decrease of -47.01% compared to the previous year's 568,000. Losses were -34.86 million, 27.4% more than in 2019.

Financial numbers in millions CAD.
Financial Statements